All the latest news and stories about Alzheimer's disease, dementia and the brain.

Each application was reviewed by experts in the field of dementia research, as well as volunteers with lived experience of dementia, to ensure that the projects receiving funding have the potential to truly make a difference for people living with dementia and caregivers.

On July 2, 2024, the United States Food and Drug Administration granted full approval to the drug donanemab (brand name Kisunla). Health Canada accepted the drug for review in February 2024.

On July 6, 2023, the United States Food and Drug Administration granted full approval to the drug lecanemab (brand name Leqembi). This drug aims to slow the progress of Alzheimer's disease. Health Canada began to review the drug in May 2023.

Is the dementia information you’re reading trustworthy? These 5 tips will help you decide.

Christopher Barry will join the Society on June 1, 2023 as CEO

On May 3, 2023, American drug company Eli Lilly and Company released some results from a Phase 3 trial of donanemab, a drug that aims to target Alzheimer’s disease. Here’s what people in Canada might want to know about it.

Researchers estimate 5% to 20% of all dementia cases are Frontotemporal dementia a group of rare disorders affecting the frontal & temporal regions of the brain. Learn more here.

If you are newly diagnosed with dementia, or caring for a person living with dementia, read on for helpful tips to free dementia support and get connected to the nearest Alzheimer Society.